Particular Aspects Related to CD4+ Level in a Group of HIV-Infected Patients and Associated Acute Coronary Syndrome

• Published in: Diagnostics (Basel) 2023-08, Vol.13 (16), p.2682
• Main Authors: Bajdechi, Mircea, Gurghean, Adriana, Bataila, Vlad, Scafa-Udriște, Alexandru, Bajdechi, Georgiana-Elena, Radoi, Roxana, Oprea, Anca Cristiana, Chioncel, Valentin, Mateescu, Iuliana, Zekra, Lucia, Cernat, Roxana, Dumitru, Irina Magdalena, Rugina, Sorin
• Format: Article
• Language: English
• Subjects: acute coronary syndrome; Acute coronary syndromes; Angina pectoris; Antiviral agents; Atherosclerosis; Cardiac patients; Cardiovascular disease; CD4+ lymphocytes; chronic inflammation; Confidence intervals; Coronary heart disease; Coronary vessels; Creatinine; Development and progression; Diabetes; Drug therapy; Enzymes; Health aspects; Heart attacks; Heart surgery; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV infection; HIV patients; Hospitals; Human immunodeficiency virus; Infection; Infections; Medical imaging; Medical prognosis; Medical research; Medicine, Experimental; Mortality; Patients; Pulmonary hypertension; Regression analysis; Risk factors; Statistical significance; T cells; Vein & artery diseases
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13162682

People living with HIV infection are at high risk for cardiovascular events due to inflammation and atherosclerosis. Also, some antiretroviral therapies may contribute to the risk of cardiovascular complications. Immune status is highly dependent on the level of lymphocyte T helper CD4+. There are data suggesting that immune status and CD4+ cell count may be involved in the development of cardiovascular complications in these patients. Our study is longitudinal and retrospective and included a total number of 50 patients with HIV infection associated with acute coronary syndrome, divided into two subgroups based on the nadir of CD4+ cells. This study analyzes the relationship between the immune status of HIV patients, assessed by the nadir of the CD4+ T-cell count, and the outcome of these patients. Also, secondary endpoints were the assessment of the magnitude of coronary lesions and of thrombotic and bleeding risk assessed by specific scores. Clinical and biological parameters and also the extension and complexity of coronary lesions were assessed. Although patients with poor immune status had more complex coronary lesions and increased operative risk and bleeding risk at one year, this was not associated with significant differences in major adverse cardiac and cerebrovascular events at the 30-day and 1-year outcomes.